Ticker > Company >

Anthem Biosciences share price

Anthem Biosciences Ltd.

NSE: ANTHEM BSE: 544449 SECTOR: Pharmaceuticals & Drugs  6.19 K   8   4

829.75
0 0
BSE: 05 Sep 04:01 PM

Price Summary

Today's High

₹ 845.55

Today's Low

₹ 826.25

52 Week High

₹ 865

52 Week Low

₹ 701.75

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

46599.59 Cr.

Enterprise Value

46397.6 Cr.

No. of Shares

56.16 Cr.

P/E

92.06

P/B

7.77

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  106.78

CASH

310.95 Cr.

DEBT

108.95 Cr.

Promoter Holding

74.69 %

EPS (TTM)

₹  9.01

Sales Growth

29.85%

ROE

23.16 %

ROCE

30.79%

Profit Growth

35.06 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year29.85%
3 Year14.34%
5 Year23.81%

Profit Growth

1 Year35.06%
3 Year7.63%
5 Year40.42%

ROE%

1 Year23.16%
3 Year22.82%
5 Year31.25%

ROCE %

1 Year30.79%
3 Year28.99%
5 Year38.62%

Debt/Equity

0.0447

Price to Cash Flow

105.95

Interest Cover Ratio

77.605

CFO/PAT (5 Yr. Avg.)

0.789181092769684

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jul 2025 74.69 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 57.6321 Cr.
  • Company has been maintaining healthy ROE of 22.8198666666667% over the past 3 years.
  • Company has been maintaining healthy ROCE of 28.9905333333333% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 77.605.
  • The Company has been maintaining an effective average operating margins of 39.19558% in the last 5 years.
  • Company has a healthy liquidity position with current ratio of 4.0497.
  • The company has a high promoter holding of 74.69%.

 Limitations

  • The company has shown a poor profit growth of 7.62964792326275% for the Past 3 years.
  • The company has shown a poor revenue growth of 14.3423109942136% for the Past 3 years.
  • The company is trading at a high EV/EBITDA of 58.0952.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2025
Net Sales 538.01
Total Expenditure 342.58
Operating Profit 195.43
Other Income 27.73
Interest 1.61
Depreciation 22.61
Exceptional Items 0
Profit Before Tax 198.94
Tax 50.6
Profit After Tax 148.34
Adjusted EPS (Rs) 2.64

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 1103.24 1231.26 1056.92 1417.54 1840.65
Total Expenditure 695.5 665.8 633.88 912.53 1151.44
Operating Profit 407.74 565.45 423.04 505.01 689.21
Other Income 37.21 48.98 85.35 70.52 109.44
Interest 16.97 10.09 8.71 9.26 9.29
Depreciation 62.4 57.76 63.7 81.49 77.94
Exceptional Items 0 0 61.8 0 0
Profit Before Tax 365.58 546.59 497.78 484.77 711.42
Tax 94.27 140.6 112.11 109.99 205.24
Net Profit 271.31 405.99 385.67 374.78 506.19
Adjusted EPS (Rs.) 4.92 7.12 6.76 6.7 9.05

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 8.48 8.78 114.1 111.82 111.82
Total Reserves 692.99 1346.69 1627.52 1821.26 2361.4
Borrowings 19.72 5.9 85.06 65.72 47.03
Other N/C liabilities 13.79 18.83 -11.18 -18.24 5.81
Current liabilities 284.88 223.05 267.61 422.26 450.18
Total Liabilities 1019.87 1603.24 2083.11 2402.82 2976.23
Assets
Net Block 361.41 329.01 448.89 477.71 624.06
Capital WIP 18.59 152.68 143.41 155.91 57.94
Intangible WIP 0 0 0 0 0
Investments 0 0 6.31 12.7 117.08
Loans & Advances 23.95 23.76 49.29 190.52 351.58
Other N/C Assets 0.12 0.72 0.58 0.49 2.5
Current Assets 615.81 1097.08 1434.63 1565.49 1823.07
Total Assets 1019.87 1603.24 2083.11 2402.82 2976.23
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 365.58 546.59 497.78 484.77 711.42
Adjustment 77.39 47.85 26.91 37.17 36.05
Changes in Assets & Liabilities -94.43 -138.1 -90.71 -237.54 -148.64
Tax Paid -71 -123 -115 -120 -159
Operating Cash Flow 277.55 333.35 318.98 164.41 439.84
Investing Cash Flow -196.09 -205.78 -377.91 -191.76 -246.31
Financing Cash Flow -63.27 180.68 52.85 -131.59 -66.42
Net Cash Flow 18.19 308.24 -6.07 -158.95 127.1

Corporate Actions

Investors Details

PARTICULARS Jul 2025%
promoters 74.69
ajay bhardwaj 42.53
aruna ganesh 1.52
ganesh sambasivam 8.13
ishaan bhardwaj 10.16
k c ravindra 7.77
krithika ganesh 1.52
s vijayalakshmi 1.02
swara trust (trustee k c ... 1.02
vira trust (trustee k c r... 1.02
PARTICULARS Jul 2025%
investors 25.31
malay jiban barua 2.27
portsmouth technologies l... 2.74
rupesh narharrao kinekar 2.27
satish s sharma 2.27
viridity tone llp 3.80

Annual Reports

Title Link
Title Link
 No Annual reports exist for this company.Report us

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit and Research reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation and Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Anthem Biosciences Stock Price Analysis and Quick Research Report. Is Anthem Biosciences an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Anthem Biosciences. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Anthem Biosciences has a PE ratio of 92.0659928326547 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Anthem Biosciences has ROA of 18.8207% which is a good sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Anthem Biosciences has a Current ratio of 4.0497.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Anthem Biosciences has a ROE of 23.1562%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Anthem Biosciences has a Debt to Equity ratio of 0.0447 which means that the company has low proportion of debt in its capital.

  • Sales growth: Anthem Biosciences has reported revenue growth of 29.8482% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Anthem Biosciences for the current financial year is 37.4437202615099%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Anthem Biosciences is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Anthem Biosciences is Rs 9.0131. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Anthem Biosciences in Ticker for free. Also, one can get the intrinsic value of Anthem Biosciences by using Valuation Calculators, which are available with a Finology ONE subscription. 

Anthem Biosciences FAQs

Q1. What is Anthem Biosciences share price today?
Ans: The current share price of Anthem Biosciences is Rs 829.8.

Q2. What is the market capitalisation of Anthem Biosciences?
Ans: Anthem Biosciences has a market capitalisation of Rs 46602.40203198 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Anthem Biosciences?
Ans: The PE ratio of Anthem Biosciences is 92.0659928326547 and the P/B ratio of Anthem Biosciences is 7.77146753178641, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Anthem Biosciences share?
Ans: The 52-week high share price of Anthem Biosciences is Rs 864.9, and the 52-week low share price of Anthem Biosciences is Rs 701.9.

Q5. Does Anthem Biosciences pay dividends?
Ans: Currently, Anthem Biosciences does not pay dividends. Dividend yield of Anthem Biosciences is around 0%.

Q6. What are the face value and book value of Anthem Biosciences shares?
Ans: The face value of Anthem Biosciences shares is Rs 2, while the book value per share of Anthem Biosciences is around Rs 106.7752. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Anthem Biosciences?
Ans: Anthem Biosciences has a total debt of Rs 108.9547 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Anthem Biosciences?
Ans: The ROE of Anthem Biosciences is 23.1562% and ROCE of Anthem Biosciences is 30.7875%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Anthem Biosciences a good buy for the long term?
Ans: The Anthem Biosciences long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Anthem Biosciences undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Anthem Biosciences appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Anthem Biosciences’s financials?
Ans: You can review Anthem Biosciences’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Anthem Biosciences

Anthem Biosciences Share Price, Financials & Company Analysis

Anthem Biosciences Limited, founded in 2006, is an innovation-driven company operating in the Pharmaceuticals & Drugs sector. It functions as a Contract Research, Development, and Manufacturing Organization (CRDMO), providing integrated services that span the entire pharmaceutical lifecycle from drug discovery and development to manufacturing. The company serves a diverse global clientele, including emerging biotech firms and major pharmaceutical corporations.

Business Model and Operations

Anthem Biosciences operates with a focus on research and innovation, offering a wide array of services. Its core competencies include organic synthesis, process development, and regulatory compliance. The company is one of the few in India with integrated capabilities for both New Chemical Entities (NCEs) and New Biological Entities (NBEs).

The business model is centered on providing one-stop solutions for its partners. This includes preclinical animal studies, development of proteins and monoclonal antibodies, and the R&D and manufacturing of highly potent compounds. Anthem also produces specialty ingredients and fermentation-based Active Pharmaceutical Ingredients (APIs) such as probiotics, enzymes, and peptides.

Get the Latest Anthem Biosciences Data Here

This page on Finology Ticker provides the most current data on Anthem Biosciences Ltd. From its share price and comprehensive financial statements to key valuation ratios, you can access all the necessary information for a detailed analysis. All data is updated daily to ensure you have the most recent figures available.

Frequently Asked Questions (FAQs)

Q1: Where can I find the live Anthem Biosciences Share Price chart?
The live and historical Anthem Biosciences Share Price chart is available on this page. The chart is updated with the latest market data, allowing you to track its performance in real-time.

Q2: How can I check the PE and PB Ratio for Anthem Biosciences Ltd.?
You can find the latest PE (Price to Earnings) Ratio and PB (Price to Book) Ratio for Anthem Biosciences on this page. These essential valuation metrics are updated daily to reflect the most current information.

Q3: Are the latest financial statements for Anthem Biosciences available here?
Yes, the company’s complete financial statements, including the Profit & Loss statement, Balance Sheet, and Cash Flow statement, are available above. This page provides the latest quarterly and annual financial data for your analysis.

Q4: What industry does Anthem Biosciences Ltd. operate in?
Anthem Biosciences Ltd. operates in the Pharmaceuticals & Drugs sector as a Contract Research, Development, and Manufacturing Organization (CRDMO).

Q5: Where can I find all the financial data for Anthem Biosciences Ltd.?
All crucial financial data for Anthem Biosciences Ltd. is available on this Finology Ticker page. This includes key ratios, corporate actions, shareholding patterns, and comparisons with industry peers, with all information updated on a daily basis.

Read More
X